Literature DB >> 12356201

Multiple sclerosis functional composite: impact of reference population and interpretation of changes.

B M J Uitdehaag1, H J Adèr, T J A Roosma, V de Groot, N F Kalkers, C H Polman.   

Abstract

The Multiple sclerosis functional composite (MSFC) has been recommended as a clinical outcome measure to be used in future MS trials. A specific characteristic of the MSFC is that it is defined as a measure of impairment relative to a reference population. Using different reference populations affects actual MSFC scores. If the selection of a reference population also has an effect on sensitivity to change of the MSFC, comparison of data from clinical trials will be almost impossible when different reference populations are used We studied the effect of the selection of a reference population on the outcome of a trial by simulating 343 intervention trials and comparing results obtained by using three different reference populations: two previously published MS patient populations and a healthy population. Scores of the healthy population were collected in the first part of the study. The effects of sex, age and education level on test scores of healthy subjects were studied as well. In the healthy controls, sex, age and education level had a different impact on individual test scores of MSFC components and overall MSFC score. Our study shows that, with the use of the MSFC, the selection of different reference populations does not affect the trial statistics and significance, but it does affect comparability of results between different trials, and complicates the dinical interpretation of any observed change.

Entities:  

Mesh:

Year:  2002        PMID: 12356201     DOI: 10.1191/1352458502ms835oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  7 in total

1.  Long-term exercise improves functional impairment but not quality of life in multiple sclerosis.

Authors:  Anders Romberg; Arja Virtanen; Juhani Ruutiainen
Journal:  J Neurol       Date:  2005-03-16       Impact factor: 4.849

2.  Regional grey matter atrophy in clinically isolated syndromes at presentation.

Authors:  R G Henry; M Shieh; D T Okuda; A Evangelista; M L Gorno-Tempini; D Pelletier
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-05-09       Impact factor: 10.154

3.  Structural connectivity-defined thalamic subregions have different functional connectivity abnormalities in multiple sclerosis patients: Implications for clinical correlations.

Authors:  Alessandro d'Ambrosio; Milagros Hidalgo de la Cruz; Paola Valsasina; Elisabetta Pagani; Bruno Colombo; Mariaemma Rodegher; Giancarlo Comi; Massimo Filippi; Maria A Rocca
Journal:  Hum Brain Mapp       Date:  2017-09-07       Impact factor: 5.038

Review 4.  Outcome Measures in Clinical Trials for Multiple Sclerosis.

Authors:  Caspar E P van Munster; Bernard M J Uitdehaag
Journal:  CNS Drugs       Date:  2017-03       Impact factor: 5.749

5.  Functional Connectivity Alterations Reveal Complex Mechanisms Based on Clinical and Radiological Status in Mild Relapsing Remitting Multiple Sclerosis.

Authors:  Gloria Castellazzi; Laetitia Debernard; Tracy R Melzer; John C Dalrymple-Alford; Egidio D'Angelo; David H Miller; Claudia A M Gandini Wheeler-Kingshott; Deborah F Mason
Journal:  Front Neurol       Date:  2018-08-20       Impact factor: 4.003

6.  Assessing the correlation between grey and white matter damage with motor and cognitive impairment in multiple sclerosis patients.

Authors:  Emilia Sbardella; Nikolaos Petsas; Francesca Tona; Luca Prosperini; Eytan Raz; Gianvito Pace; Carlo Pozzilli; Patrizia Pantano
Journal:  PLoS One       Date:  2013-05-16       Impact factor: 3.240

Review 7.  Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis.

Authors:  Sandra Meyer-Moock; You-Shan Feng; Mathias Maeurer; Franz-Werner Dippel; Thomas Kohlmann
Journal:  BMC Neurol       Date:  2014-03-25       Impact factor: 2.474

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.